The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study von Weil, Gary J, Weil, Gary J, Bogus, Joshua, Bogus, Joshua, Christian, Michael, Christian, Michael, Dubray, Christine, Dubray, Christine, Djuardi, Yenny, Djuardi, Yenny, Fischer, Peter U, Fischer, Peter U, Goss, Charles W, Goss, Charles W, Hardy, Myra, Hardy, Myra, Jambulingam, Purushothaman, Jambulingam, Purushothaman, King, Christopher L, King, Christopher L, Kuttiat, Vijesh Sridhar, Kuttiat, Vijesh Sridhar, Krishnamoorthy, Kaliannagounder, Krishnamoorthy, Kaliannagounder, Laman, Moses, Laman, Moses, Lemoine, Jean Frantz, Lemoine, Jean Frantz, O’Brian, Katiuscia K, Robinson, Leanne J, Robinson, Leanne J, Samuela, Josaia, Samuela, Josaia, Schechtman, Kenneth B, Schechtman, Kenneth B, Sircar, Anita, Sircar, Anita, Srividya, Adinarayanan, Srividya, Adinarayanan, Steer, Andrew C, Steer, Andrew C, Supali, Taniawati, Supali, Taniawati, Subramanian, Swaminathan, Subramanian, Swaminathan, Group, the DOLF IDA Safety Study, Group, the DOLF IDA Safety Study, Kaldor, John, Kaldor, John, https://orcid.org/0000-0002-7639-4355, Romani, Lucia, Romani, Lucia, https://orcid.org/0000-0001-9038-5300

Volltext bestellen